🔴 Ultragenyx is trading 5.32% down today amid market pressure and a pullback after gains

Ultragenyx is trading 5.32% down at $14.79 as broader risk-off sentiment weighs on equities.

• Nasdaq is down 1.00% and S&P 500 is down 0.55%; biotech is outperforming the broader market.
• Shares gained 6.59% on September 22 and 12.58% on September 17 after FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome type A. Today’s decline appears tied to market-wide pressure and a pullback after recent gains, not a new company-specific negative announcement.